There are also regulatory agencies emany places around Phone Number Data the world that are pConsider this vaccine To add indications and expand itcovers teenagers and is used asNeedle activation And aside from a COVID-19 vaccine, Novavax is in the pipelineEvaluating hybrid vaccines forPrevention of COVID-19 disease and influenza (CIC) in Phase 1/2 clinical trials of the 4 strains of influenza vaccine that the company is developing and is still undergoing evaluationOmi species-specific DNACron too (NVX-CoV2515) as the vaccine protects againstcan get both traditional breedsM and Omicron These vaccines incorporate an adjuvantEffectiveness using saponin which isHigh levelProtect and stimulate negative antibodiesNovavax's proprietary Matrix-M to enhance immune response Forward-looking statements This press release contains informationForecasts Investors should not rely on tStatement that has the characteristic ofThese future predictionsToo much This includes but is not limited to Message aboutNovavax's capabilitiesTo complete the offeringEnd of period and conditions Conditions of the offering Net incomeEstimated from the offering and Novavax plansTo use the income Novavax cautions that tThese forward-looking statementsRisk and uncertaintylots of sleep This may cause the results to be inaccurate.

Significantly different from what is shown oris implied in the said message. Risks and uncertainties thatInvolving, including but not limited toyong, risks associated withNovavax OfferingWill the achievement be achieved on time?according to the expected conditions Or will it be successful or not? and the possible impacts tMarket price of common shares. Novavax management also requested to useComprehensive discretion regardingNet income allocationfrom this offering Other risks involved include: i=25>The risks listed in the section "Risk Factors" and elsewhere in Novavax's Annual Report on Form 10-K for the year ended December 31, 2021 and Novavax's Quarterly Report on Form 10-K. 10-Q for the quarter ended June 30, 2022, in addition to other risk factors that Novavax will disclose.as appropriate in the report filedAdd to SEC Forward-looking statements in KThis press release reflects information as of the date of this publication only. Novavax is not affiliated.in improving or correctingThese words Novavax's business is risky.Yong and many uncertainties Including those referenced above, investors, those interested in investing. and other persons should assess the risks and risks i=35>Of course these carefully.